Clinical trials: Patients With Type 2 Diabetes
Diabetes Mellitus Type 2
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
This study will assess the potential pharmacodynamic and potential pharmacokinetic interaction between GK Activator (2) and glyburide, in type 2 diabetes patients not adequately controlled with glyburide as standard prescribed…
- Trial name
- NCT00388986
- Testing
- GK Activator (2), Glyburide
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus, Hypercholesterolemia
Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia
To assess the efficacy and safety of rosuvastatin/ezetimibe combination therapy compared to rosuvastatin monotherapy in Korean patients with type 2 diabetes mellitus and hypercholesterolemia
- Trial name
- NCT03446261
- Testing
- Rosuvamibe® Tab, Monorova® Tab
- Where
- 2 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yuhan Corporation
Type 2 Diabetes
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes
This trial is designed to compare the effects of twice-daily (before lunch and before dinner) exenatide plus oral antidiabetic (OAD) agents and twice-daily (before breakfast and before dinner) exenatide plus OAD with respect to…
- Trial name
- NCT00359879
- Testing
- exenatide
- Where
- 15 sites in Brazil, Mexico
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00800176
- Testing
- RO4998452
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus…
- Trial name
- NCT01650259
- Testing
- OAD, Trazenta
- Where
- Japan
- Volunteers
- 4,876 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT02851849
- Testing
- LGD-6972-5 mg, LGD-6972-10 mg, LGD-6972-15 mg
- Where
- 29 sites in United States
- Volunteers
- 148 people
- Sponsor
- Ligand Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking metformin for type 2 diabetes.
- Trial name
- NCT00792935
- Testing
- MK-0941, Glimepiride, Metformin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00877526)
- Testing
- No treatment given
- Where
- Malaysia
- Volunteers
- 1,670 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effectiveness of basal insulin analog and insulin analog mid mixture in Chinese participants with type 2 diabetes mellitus.
- Trial name
- CLASSIC (NCT03018938)
- Testing
- Insulin Analog Mid Mixture, Basal Insulin Analog
- Where
- 32 sites in China
- Volunteers
- 814 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 2
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug…
- Trial name
- NCT00237237
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 588 people
- Sponsor
- Novartis
Type 2 Diabetes
Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage
The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy
- Trial name
- NCT01275794
- Where
- 23 sites in Russia
- Volunteers
- 1,849 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
This study is not being conducted in the United States. The purpose of this study is to assess the effect of vildagliptin, an unapproved drug, on various measures of pancreatic islet function in people with type 2 diabetes who…
- Trial name
- NCT00260156
- Testing
- vildagliptin
- Where
- Switzerland
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of TA-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days).
- Trial name
- NCT00707954
- Testing
- TA-7284
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India
The purpose of the India iPro2 study is to demonstrate that iPro2 Continuous Glucose Monitoring System (CGMS) evaluation enables Health Care Professional (HCP)s treating patients in India with type 2 diabetes to get a better…
- Trial name
- NCT01995539
- Testing
- therapy regimen
- Where
- 11 sites in India
- Volunteers
- 181 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation.
- Trial name
- NCT02140645
- Testing
- linagliptin
- Where
- United States
- Volunteers
- 166,613 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes
The study will demonstrate the effect of 24 weeks of treatment with vildagliptin compared to placebo on insulin sensitivity in patients with type 2 diabetes mellitus (T2DM) treated with metformin, assessed as glucose Rd (rate of…
- Trial name
- NCT01356381
- Testing
- Vildagliptin
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels.
- Trial name
- NCT02703337
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.